•Baseline levels of serum LOXL2, FibroSure/FibroTest, NAS, and severity of steatosis, lobular inflammation, and ballooning were not associated with fibrosis improvement in either group, nor were changes in serum fibrosis markers over time (apart from LOXL2 in patients with bridging fibrosis at baseline). This evidence concerns the gene LOXL2 and fibrosis.